Maisie Borrows

1 POSTS 0 COMMENTS
Maisie Borrows is the Research Manager at Reform and has a particular interest in health policy and digital public services. Before Reform, Maisie worked as a management consultant at PwC.

Latest articles

Investigational therapy has potential to become first oral GLP-1 receptor agonist for those living with type 2 diabetes

Novo Nordisk presents oral semaglitude data at ENDO

Oral semaglutide 7 mg and 14 mg doses showed superior reductions in blood sugar and weight compared to sitagliptin at 26 weeks in data...
Pf Award Winners

Pf Award Winners on the positive patient outcomes that come from working together

The winners of the Joint Working Pf Award 2018, Senior Coloplast Care Nurse Ruth Christer and NHS Partnership Manager, Coloplast, Jonathan Walker, on the...
Brain scan image: Detecting and managing atrial fibrillation

Detecting and managing atrial fibrillation

The ‘Podiatry and Atrial Fibrillation – Save a life, stop a stroke’ webinar was created to improve the detection and management of atrial fibrillation,...

Popular articles

Brain scan image: Detecting and managing atrial fibrillation

Detecting and managing atrial fibrillation

The ‘Podiatry and Atrial Fibrillation – Save a life, stop a stroke’ webinar was created to improve the detection and management of atrial fibrillation,...
Samsung Bioepis Announces Three-year Follow-up Data for Biosimilar ONTRUZANT® (trastuzumab) in Early or Locally Advanced HER2-positive Breast Cancer

Samsung Bioepis announces three-year follow-up data for biosimilar ONTRUZANT® (trastuzumab)

Samsung Bioepis announces three-year follow-up data for biosimilar ONTRUZANT® (trastuzumab) in early or locally advanced HER2-positive breast cancer. Samsung Bioepis has announced the findings of...
The future of genomics

The future of genomics and precision medicine

How is the use of genomics data enhancing our medical understanding and what does this mean for the future of precision medicine? Genomics is one of...
Investigational therapy has potential to become first oral GLP-1 receptor agonist for those living with type 2 diabetes

Novo Nordisk presents oral semaglitude data at ENDO

Oral semaglutide 7 mg and 14 mg doses showed superior reductions in blood sugar and weight compared to sitagliptin at 26 weeks in data...
Image of graduates: skills shortage in life sciences

Addressing the skills shortage in life sciences

How can collaboration help to fill the skills shortage gap to ensure that the UK can compete in the global future of life sciences? The...